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Abstract  
Cadmium (Cd) is classified as a carcinogen in humans (IA). In addition to causing lung cancer, 
the incidence of prostate cancer due to Cd exposure based on epidemiological research has also 
increased. This study aims to identify the GSTP1 genotypic frequency distribution and its 
correlation with PSA and IGF-1 levels in Cd exposed and unexposed workers. The research 
design used was cross sectional in 23 exposed groups (weld workers) and 40 unexposed groups 
(office employees) with a total of 63 people. The measurement of PSA and IGF-1 levels was 
carried out using the ELISA method and identification of the GSTP1 gene polymorphism using 
the PCR-RFLP method. Data analysis using Mann-Whitney and Spearman correlation test. The 
results showed that there was a relationship between PSA levels and IGF1 (p <0.01, r = 0.515) in 
all subjects. The results of identification of GSTP1 gene polymorphism were obtained as ile/ile 
genotypes as much as 30.2% and ile/val as much as 69.8%. There were no differences in PSA and 
IGF1 levels between ile/ile and ile/val genotypes (p> 0.05). There was a relationship between 
PSA and IGF1 (p <0.01, r = 0.569) in the group of Cd exposed workers and no differences in PSA 
and IGF1 levels between the ile/ile and ile/val genotypes (p> 0.05). There was a relationship 
between PSA and IGF1 (p <0.05, r = 0.342) in the unexposed group of workers and no differences 
in PSA and IGF1 levels between ile/ile and ile/val genotype (p>  0.05).  
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Introduction  
Cadmium (Cd) is thought to cause 
prostate cancer because in addition to the 
kidneys and liver, Cd is also accumulated in 
the prostate and testes.  Several studies has 
found the association between Cd and 
prostate cancer deaths (Julin et al.,  2012; 
Lin et al., 2013). Prostate Specific Antigen 
(PSA) can be used to detect early stage 
prostate cancer, clinical and monitoring after 
therapy with a limit of 4 ng / ml. Prostate 
specific antigen is a protein that is normally 
secreted exclusively by the prostate gland to 
help nourish sperm. However, if there is an 
increase in PSA levels above the normal 
level detected, it can be ascertained that 
there is a problem in the prostate. These 
problems can include malignancy (prostate 
cancer) or benign abnormalities (prostatitis 
and benign prostatic hyperplasia). After the 
use of PSA examination in the clinical world 
there was an increase in detection of prostate 
cancer by about 81% compared to before 
which only uses rectal examination (Baade 
et al., 2009).  
Cd causes prostate cancer through 
several mechanisms, the initiation of 
malignant transformation, the nature of Cd 
as a substance that has activities such as 
androgen, antiapoptotic and mitogenic 
(Aimola et al., 2012; Arriazu et al., 2013; 
Lacorte et al., 2011). The antiapoptotic and 
mitogenic mechanism of Cd as cause of 
prostate cancer can be assessed with the 
Insulin Growth Factor1 (IGF1) indicator. 
Men with the highest quartile IGF1 levels 
have a 2.6 risk of prostate cancer 
(Chokkalingam et al., 2001).  
 
 
Prostate cancer growth is affected by the 
presence of oxidative stress and reactive 
oxygen species. One of the genes involved 
in carcinogen detoxification and antioxidant 
activity is Glutathione S-transferase P1 
(GSTP1) (Qadri et al., 2011). The presence 
of a polymorphism in this gene will cause a 
decrease in the elimination of carcinogens 
and may increase IGF1 and PSA levels. The 
aim of the study was to determine the 
differences PSA and IGF1 levels on the 
GSTP1 gene polymorphism in the Cd 
exposed group and unexposed group.  
  
Method 
This study was part of Cd 
carcinogenesis study on worker with cross 
sectional design. The research was carried 
out in 8 months (January to August 2015) 
and was located in Purwokerto and 
Banyumas City, Banyumas District, Central 
of Java, Indonesia. The subjects of the 
research came from two groups of workers. 
The Cd exposure group were 23 welding 
workers and the group of workers unexposed 
to Cd were 40 office workers. Samples were 
selected by consecutive sampling in 
accordance with the inclusion criteria, which 
were males over 30 years of age and having 
worked in the workplace for a minimum of 
6 months. The exclusion criteria was 
acquiring an acute illness (elevated body 
temperature) during the last 4 months.   
Blood samples were collected from the 
median cubital vein. Prior to blood 
sampling, the subjects were asked to fast for 
10 hoursand not to have sexual intercourse 
during 2x24 hours. PSA and IGF-1 levels 
were determined using human Elisa kit 
(Sunred Biotechnology Company, Ltd, 
Shanghai), based on the principle of the 
double-antibody sandwich technique, and 
assayed on an Elisa Reader 270 
(Biomeureux, France).   
The exon 5 polymorphic site in GSTP1 
locus (Ile105Val) was detected by restriction 
fragment length polymorphism (RFLP) of 
PCR-amplified fragments.The primers used 
were: P105F: 5'-ACC CCA GGG CTC TAT 
GGG AA-3' and P105R: 5'-TGA GGG CAC 
AAG AAG CCC CT-3'. PCR was carried out 
in a 30-μL vol-ume containing about 50 ng 
genomic DNA template, 200 μM of each 
dNTP, 200 ng of each primer, 1.5 mM 
MgCl2, 1X PCR buffer (50 mM KCl, 10 
mM Tris-HCl, pH 8.3), and 1 U Taq DNA 
polymerase (Promega, Southampton, UK). 
After an initial denaturation step of 10 min 
at 95°C, the samples were processed through 
30 temperature cycles of 30 s at 94°C, 30 s 
at 55°C, and 30 s at 72°C. A final extension 
step of 72°C for 10 min was performed. The 
176-bp PCR products (20 μL) were digested 
for 2 h at 37°C with 2 U Alw26I (Fermentas 
Inc., Vilnius, Lithuania). The detection of 
the different alleles was carried out by 
horizontal 4% agarose gel electrophoresis 
with ethidium bromide, along with a 100-bp 












Figure 1. PCR-restriction fragment 
length polymorphism analysis of the 
GSTP1 Ile105Val polymorphism. The 
consensus sequence corresponding to the 
GSTP1 Iso allele was not cut, whereas 
the Val sequence corresponding to the 
GSTP1 Val allele was cleaved to yield 
two fragments (91 and 85 bp). Lane 6 = 
Wild-type homozygote (GSTP1 Ile/Ile); 
lanes 2-5 and lanes 7-8 = heterozygote 
(GSTP1Iso/Val); lane 1 = 100-bp DNA 
ladder. 
  
Data analysis to determine differences 
between groups was by means of the 
MannWhitney test, because the data were 
not normally distributed.   Data analysis to 
determine whether there was a correlation, 








The mean age of exposed group was 40,31 ± 6,47, unexposed group was 38,50 ± 7,60 and the all 
subjects was 39,10 ± 7,01 years (Table 1).  
Table 1. Subjects characterization 
Group  Age (yr)  
All workers (n=63)  39,10 ± 7,01  
Exposed workers (n=23)  40,31 ± 6,47  
Unexposed workers (n=40)  38,50 ± 7,60  
  
The results of GSTP1 gene polymorphism were obtained as ile/ile genotypes 30.2% and ile/val 
69.8% in all subjects, ile/ile genotypes 52.2% and ile/val 47.8% in exposed workers, ile/ile 
genotypes 17.5% and ile/val 82.5% in unexposed workers (Table 2).   
Table 2. GSTP1 polymorphism distribution 
GSTP1 polymorphism  Ile/ile  Ile/val  
All workers (n=63)  19 (30,2)  44 (69,8)  
Exposed workers (n=23)  12 (52,2)  11 (47,8)  
Unexposed workers (n=40)  7 (17,5)  33 (72,5)  
  
There were no differences in PSA and IGF1 levels between the ile/ile and ile/val genotypes (p> 
0.05) in the all subjects, group of Cd exposed workers and unexposed workers (Table 3 and 4).  
Table 3. Differences of PSA level 
  Ile/ile  Ile/val  P  
All workers (n=63)  3,05 ± 1,15  3,17 ± 4,11  0,095  
Exposed workers  
(n=23)  
3,63 ± 1,00  2,82 ± 1,37  0,406  
Unexposed workers  
(n=40)  
2,06 ± 0,58  2,64 ± 3,17  0,873  
  
Table 4. Differences of IGF1 level 
  Ile/ile  Ile/val  P  
All workers (n=63)  6,54 ± 3,63  11,3 ± 25,09  0,952  
Exposed workers  
(n=23)  
7,75 ± 3,95  4,99 ± 2,29  0,065  
Unexposed workers  
(n=40)  
4,46 ± 1,74  9,46 ± 17,97  0,144  
  
There was a relationship between PSA and IGF1 in the all subjects (p <0.01, r = 0.515), Cd 
exposed workers (p <0.01, r = 0.569) and unexposed workers (p <0.05, r = 0.342) (table 5).   
Table 5. IGF1 and PSA correlation 
  p  r  
All workers (n=63)  0,000*  0,515  
Exposed workers (n=23)  0,005*  0,569  
Unexposed workers (n=40)  0,031*  0,342  




This study investigated the differences 
in levels of IGF1 and PSA levels on the 
GSTP1 gene polymorphisms between Cd 
exposed workers and unexposed workers. 
Since, the polymorphism in GSTP1 gene 
will decrease elimination of carcinogens, 
which can increased risk of prostate cancer. 
Insulin-like growth factors (IGF-I, IGF-II) 
and their binding proteins (IGFBP-1-6) play 
a key role in cell proliferation, 
differentiation and apoptosis, suggesting    
possible involvement in carcinogenesis. 
Meta-analysis confirms that raised 
circulating lGF-I is positively associated 
with prostate cancer risk (Rowlands et al., 
2009).  
We tried to confirm that glutathione S-
transferase (GST) polymorphisms could 
enhanced oxidative stress on Cd exposed 
and unexposed workers. In our current 
study, we investigated 23 Cd exposed 
workers and 40 unexposed workers. We 
found the frequency of the ile/ile genotypes 
30.2% and ile/val 69.8% in all subjects, 
ile/ile genotypes 52.2% and ile/val 47.8% in 
exposed workers, ile/ile genotypes 17.5% 
and ile/val 82.5% in unexposed workers. 
The range of Ile allele frequency was 0.47–
0.86 in Africans, 63–76% in Europeans, 67–
92% in Asians and 59–84% in Indians. The 
range of Val105/Val105 allele was 14–53% 
in Africans, 23– 37% in Caucasians, 8–33% 
in Asians and 16–41% in Indians (Sharma et 
al., 2014). Qadri et al. found the frequency 
of the three different genotypes of GSTP1 
Ile105Val in Kashmir ethnic population, i.e., 
Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 
and 14.3% among prostate cancer cases, 
48.5, 37.5 and 14% among benign prostate 
hyperplasia cases and 73.8, 21.3 and 5% in 
the control population. There was a 
significant association between the GSTP1 
Ile/Val genotype and the advanced age group 
among the cases and conclude that GSTP1 
Ile/Val polymorphism is involved in the risk 
of prostate cancer development (Qadri et al., 
2011).  
Circulating levels of IGF-I and its main 
binding protein, IGF binding protein 3 
(IGFBP-3), have been associated with risk 
of several types of cancer. Whereas higher 
IGF-1 levels were associated with increased 
prostate cancer risk. The associations were 
primarily driven by lower-grade and non-
advanced prostate cancer (Cao et al., 2015). 
There is no differences level of IGF1 
between the ile/ile and ile/val genotypes in 
the all subjects, group of Cd exposed 
workers and unexposed workers.These 
findings were consistent with Henningson et 
al. in healthy women from breast cancer 
high-risk families (Lima et al., 2008).  
In this study, there is no difference level 
of PSA between the ile/ile and ile/val 
genotypes in the all subjects, group of Cd 
exposed workers and unexposed workers. 
These were consistent with Lima et al. in the 
Brazilian population. There was no 
association between GSTP1 genotypes and 
possible clinical factors of risk or any 
parameter of tumour aggressiveness at 
diagnosis or during follow-up such as PSA 
(13). Meta-analysis by Wei et al. showed 
that GSTP1 Ile105Val polymorphism might 
not be significantly associated with overall 
prostate cancer risk (Wei et al., 2013).  
IGF-1 modulates cell growth and 
survival, and is thought to be important in 
tumor development. The association 
between IGF-1 and prostate cancer risk is 
well established. Our study found there was 
correlation between IGF-1 and PSA. IGF-1 
has been shown to stimulate the proliferation 
of human prostate epithelial cells in culture 
and to be necessary for normal growth and 
development of the rat and mouse prostate. 
Epidemiological studies have established a 
link between high circulating serum IGF-1 
levels and the risk of later developing 
advanced prostate cancer, and 
overexpression of IGF-1 in the prostate basal 
epithelial layer of transgenic mice results in 
prostate adenocarcinoma that is similar to 
human disease. Thus, IGF-1 action appears 
to be important for prostate cancer initiation 
(Roberts , 2004).  
  
Conclusion 
Hence, in this study, we observed that 
IGF-1 and PSA in Cd exposed or unexposed 
workers was not affected by their 
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